SCHEMBL6495407

SCHEMBL6495407

COC(=O)c1c(-c2ccccc2)[nH]c2cc(N)ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.50
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
KMT2A Q03164 2/20 0.49
HSD17B10 Q99714 2/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
MAPK10 P53779 1/20 0.49
TUBB4A P04350 5/20 0.48
TUBB P07437 5/20 0.48
TUBA3C P0DPH7 5/20 0.48
TUBA1B P68363 5/20 0.48
TUBA4A P68366 5/20 0.48
TUBB4B P68371 5/20 0.48
TUBB3 Q13509 5/20 0.48
TUBB2A Q13885 5/20 0.48
TUBB8 Q3ZCM7 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28285243 0.86 ALDH1A1 (0.65) KDM4EMEN1ALDH1A1HPGDKMT2A
SCHEMBL5438097 0.84 NR4A2 (0.69) NR4A2KDM4EMEN1ALDH1A1HPGD
SCHEMBL6493095 0.81 TLR8 (0.43) NR4A2KDM4EMEN1ALDH1A1HPGD
SCHEMBL28435543 0.80 NR4A2 (0.63) NR4A2KDM4EMEN1ALDH1A1HPGD
SCHEMBL14564439 0.80 KIF11 (0.56) NR4A2KDM4EMEN1ALDH1A1HPGD
SCHEMBL10314414 0.78 MDM4 (0.46) MEN1KMT2ALMNATUBB4ATUBB
SCHEMBL14709940 0.76 NR4A2 (0.61) NR4A2KDM4EMEN1ALDH1A1HPGD
SCHEMBL26031834 0.74 NR4A2 (0.59) NR4A2KDM4EMEN1ALDH1A1HPGD
SCHEMBL7653286 0.73 NR4A2 (0.68) NR4A2KDM4EMEN1ALDH1A1HPGD
SCHEMBL31312750 0.73 TUBB4A (0.62) NR4A2KDM4EMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075499-A1 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075499-A1 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy CHEK2, CHEK1, CHKA NR4A2 2235/4885KDM4E 1654/4885MEN1 1194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.